These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11602811)

  • 1. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M; Mongiellová V; Huttová D; Cibulová L; Krivosíková Z; Spustová V; Dzúrik R
    J Cardiovasc Pharmacol; 2001 Nov; 38(5):651-6. PubMed ID: 11602811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of monotherapy with ciprofibrate and in combination with acetylsalicylic acid on the spectrum of lipids, thromboxane and fibrinogen in patients with atherosclerosis and hyperlipoproteinemia].
    Gajdos M; Fedelesova V; Mongiellova V; Cibulova L; Huttova D; Polak F; Krivosikova Z
    Bratisl Lek Listy; 1999 Aug; 100(8):449-53. PubMed ID: 10645034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA; Fanghänel-Salmón G; Meza E; Montes J; Gulías-Herrero A; Sánchez L; Monterrubio-Flores EA; González-Valdez H; Gómez Pérez FJ
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG; Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Mayroudi MC; Boudoulas H
    Coron Artery Dis; 1996 Nov; 7(11):843-50. PubMed ID: 8993943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E; Dejager S; Chapman MJ
    Atherosclerosis; 1993 Apr; 100(1):91-102. PubMed ID: 8318067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
    Hernández-Mijares A; Lluch I; Vizcarra E; Martínez-Triguero ML; Ascaso JF; Carmena R
    Nutr Metab Cardiovasc Dis; 2000 Feb; 10(1):1-6. PubMed ID: 10812581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC; de Valois JC; van den Ende B; Wouter ten Cate J; Kastelein JJ
    Atherosclerosis; 1996 Jul; 124 Suppl():S75-81. PubMed ID: 8831919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
    Papadakis JA; Ganotakis ES; Jagroop IA; Winder AF; Mikhailidis DP
    Int J Cardiol; 1999 Jun; 69(3):237-44. PubMed ID: 10402106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofibrate and lipid profile.
    Chandler HA; Batchelor AJ
    Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract]   [Full Text] [Related]  

  • 11. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
    Guerin M; Le Goff W; Frisdal E; Schneider S; Milosavljevic D; Bruckert E; Chapman MJ
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3738-46. PubMed ID: 12915663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
    Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
    Chapman MJ; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S21-8. PubMed ID: 8831912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E; Kostoula A; Elisaf M; Mikhailidis DP
    Angiology; 2002; 53(3):273-7. PubMed ID: 12025914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
    Okopien B; Cwalina L; Lebek M; Kowalski J; Zielinski M; Wisniewska-Wanat M; Kalina Z; Herman ZS
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):551-7. PubMed ID: 11770837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofibrate treatment in patients with atherogenic lipoprotein phenotype: effects on HDL quality, LDL susceptibility to oxidation and DNA damage.
    Raslová K; Dobiásová M; Nagyová A; Fábry R; Rauchová H; Dusinská M
    Eur J Clin Pharmacol; 1998; 54(9-10):697-9. PubMed ID: 9923570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ; O'Bryan-Tear CG
    Postgrad Med J; 1996 Dec; 72(854):739-43. PubMed ID: 9015467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel lipid-lowering properties of Vaccinium myrtillus L. leaves, a traditional antidiabetic treatment, in several models of rat dyslipidaemia: a comparison with ciprofibrate.
    Cignarella A; Nastasi M; Cavalli E; Puglisi L
    Thromb Res; 1996 Dec; 84(5):311-22. PubMed ID: 8948058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism.
    Liberopoulos E; Miltiadous G; Elisaf M
    Diabetes Obes Metab; 2001 Apr; 3(2):97-8. PubMed ID: 11298731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.